ACCC refuses to approve pharma agreement in rare patent settlement request
Australia’s antitrust authority has voiced its concerns about a proposed patent dispute settlement and licensing agreement between Celgene and two drugmakers, warning that it could distort competition between generic manufacturers.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.